The pharmaceutical firm AstraZeneca and the University of Oxford have announced that their Covid-19 vaccine is safe and effective at an average of 70.4% in asymptomatic patients. Its efficacy is up to 90% depending on the dose.
Preliminary results from the Phase III clinical trial were published this week in the prestigious scientific journal The Lancet. The study involved 11,636 patients from the United Kingdom and Brazil. It is the first peer-reviewed publication of Phase III data from studies on a coronavirus vaccine.
AZD1222 has been developed by a genetically modifying a common cold virus that affects chimpanzees.
AstraZeneca plans to manufacture up to 3 billion doses of the vaccine in 2021 on a rolling basis, pending regulatory approval.
AstraZeneca Spain, through its office in Barcelona, is a member of CataloniaBio & HealthTech.
Photo: © Oxford University
Comments